Advanced therapies in Parkinson’s Disease

In cutting edge Parkinson's malady (PD), neurologists and patients confront an unpredictable choice for a propelled treatment. While picking a treatment, the best accessible proof ought to be joined with the expert's skill and the patient's inclinations. Objective: The target of this investigation was to investigate current basic leadership in cutting edge PD. Techniques: We led centre gathering exchanges and individual meetings with patients (N = 20) who had gotten profound cerebrum incitement, Levodopa-Carbidopa intestinal gel, or subcutaneous Apo morphine implantation, and with their guardians (N = 16).

  • Gene therapy
  • Neural Degeneration
  • Neuturin Gene Therapy for Parkinson’s disease
  • Surgical therapeutics for Parkinson’s disease
  • Neurotrophic Factor

Related Conference of Advanced therapies in Parkinson’s Disease

Aug 02-04, 2017

International Meeting on CNS

Melbourne, Australia
August 29-31, 2017

15th European Neurology Congress

London, UK
August 29-31, 2017

6th World Congress on Addiction Disorder & Addiction Therapy

Prague, Czech Republic
August 31-September 01, 2017

3rdInternational Conference on Epilepsy and Treatment

Brussels, Belgium
September 07-08, 2017

Global Experts Meeting on Brain Disorders

Macau, Hong Kong
November 16-17, 2017

Global Experts Meeting on Neurological Disorders and Stroke

Melbourne, Australia
Oct 12-13, 2017

Internatinal Meeting on Addiction Congress

Osaka, Japan
Oct 12-13, 2017

Global Meeting on Dual Diagnosis and Addiction

Auckland, Newzeland
October 16-17, 2017

17th Global Neuroscience Conference

Osaka, Japan
Nov 13-14, 2017

Gobal Experts Meeting on Neuroscience and Neurochemistry

Melbourne, Australia
February 22-23, 2018

11th International Conference on Vascular Dementia

Paris, France
July 16-17, 2018

World Congress on Neurology and Neurodisorders

Melbourne, Australia

Advanced therapies in Parkinson’s Disease Conference Speakers